The Fast Track designation by the FDA is a significant regulatory milestone that can expedite the development and review process of Tamibarotene. This is likely to be viewed positively by investors, as it could bring the drug to market faster than anticipated, potentially leading to earlier revenue generation from this treatment. The designation also underscores the unmet medical need in treating newly diagnosed unfit AML patients with RARA gene overexpression, highlighting the drug's importance.